-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Nasal -X- _ B-Comparison
potential -X- _ I-Comparison
difference -X- _ I-Comparison
( -X- _ I-Comparison
NPD -X- _ I-Comparison
) -X- _ I-Comparison
and -X- _ O
intestinal -X- _ B-Intervention
current -X- _ I-Intervention
measurement -X- _ I-Intervention
( -X- _ I-Intervention
ICM -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
functional -X- _ O
CFTR -X- _ O
tests -X- _ O
that -X- _ O
are -X- _ O
used -X- _ O
as -X- _ O
adjunctive -X- _ O
diagnostic -X- _ O
tools -X- _ O
for -X- _ O
cystic -X- _ B-Patient
fibrosis -X- _ I-Patient
( -X- _ I-Patient
CF -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Smoking -X- _ O
has -X- _ O
a -X- _ O
systemic -X- _ O
negative -X- _ O
impact -X- _ O
on -X- _ O
CFTR -X- _ O
function. -X- _ O
A -X- _ O
diagnostic -X- _ O
comparison -X- _ O
between -X- _ O
NPD -X- _ B-Comparison
and -X- _ O
ICM -X- _ B-Intervention
and -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
smoking -X- _ O
on -X- _ O
both -X- _ O
CFTR -X- _ O
tests -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
done. -X- _ O
METHODS -X- _ O
: -X- _ O
The -X- _ O
sweat -X- _ O
chloride -X- _ O
test -X- _ O
, -X- _ O
NPD -X- _ O
, -X- _ O
and -X- _ O
ICM -X- _ O
were -X- _ O
performed -X- _ O
in -X- _ O
18 -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
CF -X- _ I-Patient
( -X- _ O
sweat -X- _ O
chloride -X- _ O
> -X- _ O
60 -X- _ O
mmol -X- _ O
/ -X- _ O
l -X- _ O
) -X- _ O
, -X- _ O
including -X- _ O
6 -X- _ O
pancreatic -X- _ O
sufficient -X- _ O
( -X- _ O
PS -X- _ O
) -X- _ O
patients -X- _ O
, -X- _ O
and -X- _ O
13 -X- _ B-Comparison
healthy -X- _ I-Comparison
controls -X- _ I-Comparison
, -X- _ O
including -X- _ O
8 -X- _ O
smokers. -X- _ O
The -X- _ O
NPD -X- _ O
CFTR -X- _ O
response -X- _ O
to -X- _ O
Cl-free -X- _ O
and -X- _ O
isoproterenol -X- _ O
perfusion -X- _ O
( -X- _ O
Δ0Cl -X- _ O
( -X- _ O
- -X- _ O
) -X- _ O
+ -X- _ O
Iso -X- _ O
) -X- _ O
was -X- _ O
compared -X- _ O
to -X- _ O
the -X- _ O
ICM -X- _ O
CFTR -X- _ O
response -X- _ O
to -X- _ O
forskolin -X- _ O
/ -X- _ O
IBMX -X- _ O
, -X- _ O
carbachol -X- _ O
, -X- _ O
and -X- _ O
histamine -X- _ O
( -X- _ O
ΔI -X- _ O
( -X- _ O
sc -X- _ O
, -X- _ O
forskolin -X- _ O
/ -X- _ O
IBMX+ -X- _ O
carbachol+histamine -X- _ O
) -X- _ O
) -X- _ O
. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ O
mean -X- _ B-Outcome
NPD -X- _ I-Outcome
CFTR -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
ICM -X- _ I-Outcome
CFTR -X- _ I-Outcome
response -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CF -X- _ I-Outcome
and -X- _ I-Outcome
healthy -X- _ I-Outcome
controls -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
different -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CF -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
PS -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
pancreatic -X- _ I-Outcome
insufficient -X- _ I-Outcome
( -X- _ I-Outcome
PI -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Smokers -X- _ I-Outcome
have -X- _ I-Outcome
a -X- _ I-Outcome
decreased -X- _ I-Outcome
CFTR -X- _ I-Outcome
response -X- _ I-Outcome
measured -X- _ I-Outcome
by -X- _ I-Outcome
NPD -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.049 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
For -X- _ I-Outcome
ICM -X- _ I-Outcome
there -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
trend -X- _ I-Outcome
towards -X- _ I-Outcome
decreased -X- _ I-Outcome
CFTR -X- _ I-Outcome
response -X- _ I-Outcome
( -X- _ I-Outcome
NS -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Three -X- _ I-Outcome
healthy -X- _ I-Outcome
control -X- _ I-Outcome
smokers -X- _ I-Outcome
had -X- _ I-Outcome
NPD -X- _ I-Outcome
responses -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
CF-range. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
to -X- _ I-Outcome
NPD -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
no -X- _ I-Outcome
overlap -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
ICM -X- _ I-Outcome
response -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CF -X- _ I-Outcome
and -X- _ I-Outcome
controls. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
ICM -X- _ B-Outcome
is -X- _ I-Outcome
superior -X- _ I-Outcome
to -X- _ I-Outcome
NPD -X- _ I-Outcome
in -X- _ I-Outcome
distinguishing -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CF -X- _ I-Outcome
who -X- _ I-Outcome
have -X- _ I-Outcome
a -X- _ I-Outcome
sweat -X- _ I-Outcome
chloride -X- _ I-Outcome
> -X- _ I-Outcome
60 -X- _ I-Outcome
mmol -X- _ I-Outcome
/ -X- _ I-Outcome
l -X- _ I-Outcome
and -X- _ I-Outcome
healthy -X- _ I-Outcome
controls -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
smokers. -X- _ I-Outcome
Neither -X- _ I-Outcome
NPD -X- _ I-Outcome
nor -X- _ I-Outcome
ICM -X- _ I-Outcome
differentiated -X- _ I-Outcome
between -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
CF -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
PS -X- _ I-Outcome
from -X- _ I-Outcome
those -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
PI. -X- _ I-Outcome
Smoking -X- _ I-Outcome
has -X- _ I-Outcome
a -X- _ I-Outcome
negative -X- _ I-Outcome
impact -X- _ I-Outcome
on -X- _ I-Outcome
CFTR -X- _ I-Outcome
function -X- _ I-Outcome
in -X- _ I-Outcome
healthy -X- _ I-Outcome
controls -X- _ I-Outcome
measured -X- _ I-Outcome
by -X- _ I-Outcome
NPD -X- _ I-Outcome
and -X- _ I-Outcome
challenges -X- _ I-Outcome
the -X- _ I-Outcome
diagnostic -X- _ I-Outcome
interpretation -X- _ I-Outcome
of -X- _ I-Outcome
NPD -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
ICM. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
doi:10.1186 -X- _ O
/ -X- _ O
1471-2466-14-156 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

